No Data
Neurocrine Is Maintained at Buy by UBS
Neurocrine Biosciences Analyst Ratings
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $162
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $159
Unusual Options Activity: APA, IQV and Others Attract Market Bets, APA V/OI Ratio Reaches 227.3
EST Jan 6th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options